NMRA Investors Have Opportunity to Lead Neumora Therapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

Core Viewpoint - Neumora Therapeutics, Inc. is facing a federal securities class action lawsuit due to allegations of misleading statements and inadequate data regarding its clinical trials, leading to significant investor losses following the failure of its experimental depression treatment [4][5]. Group 1: Legal Actions and Investigations - Faruqi & Faruqi, LLP is investigating potential claims against Neumora and has set an April 7, 2025 deadline for investors to seek the role of lead plaintiff in the class action lawsuit [2]. - The lawsuit alleges that Neumora and its executives violated federal securities laws by making false statements and failing to disclose critical information about their clinical trials [4]. Group 2: Financial Impact - Following the announcement of the failure of its depression treatment in the Phase III Koastal-1 trial, Neumora's stock price dropped by 81%, closing at $1.97 per share on January 2, 2025 [5]. - Investors who suffered losses exceeding $50,000 due to the IPO and related documents are encouraged to contact the law firm for discussions on their legal rights [1]. Group 3: Clinical Trial Issues - The complaint highlights that Neumora had to amend the original Phase Two Trial inclusion criteria to include a patient population with moderate to severe Major Depressive Disorder (MDD) to demonstrate the efficacy of navacaprant [4]. - It is claimed that the Phase Two Trials lacked adequate data, particularly regarding patient population size and gender ratio, which undermined the predictive accuracy for the subsequent KOASTAL-1 study [4].